1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (Omnibus) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program provides non-dilutive funding to U.S. small businesses developing innovative health, life sciences, biomedical, public health, and FDA-relevant technologies.
It supports projects from early-stage feasibility through later-stage R&D and commercialization activities. The focus areas include biomedical/behavioral research, digital health (such as AI diagnostics or mobile health apps), and AI techniques for characterizing and minimizing errors in health-related datasets.
This is a broad opportunity for technologies aligning with the missions of participating NIH Institutes, CDC Centers, or FDA Centers.
NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) participates in this program and is interested in projects that include robust timelines for commercialization, requisite fundraising, and all required regulatory milestones, particularly those supporting completion of research for an Investigational New Drug (IND) application or Investigational Device Exemption (IDE).
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
U.S. Department of Health and Human Services National Institutes of Health The SBIR and STTR programs were reauthorized on April 13, 2026. Currently, NIH has no active SBIR or STTR Notices of Funding Opportunity (NOFOs). Future NOFOs are forecasted at Grants.
gov prior to opening for applications. The next standard receipt date is September 5, 2026. Learn if your company is eligible for NIH SBIR or STTR funding, how to apply , and what to expect during each step of the application process.
Multiple registrations are required to prepare your application and apply for funding.
Small Business Program Basics Understanding SBIR and STTR Foreign Disclosure and Risk Management SBIR and STTR Grants (NOFO s ) SBIR Contract Solicitations Commercialization Readiness Pilot (CRP) Small Business Transition Grant for New Entrepreneurs Navigate NIH's Research Areas Applicant Assistance Programs --> Transition Award (Coming Soon) Our team can help you maximize the benefits from NIH programs and resources which help you bring your innovations to life.
NIH's Technical and Business Assistance (TABA) Concept to Clinic Commercializing Innovation (C3i) The NIH is actively turning discovery into health by helping small businesses develop innovative technologies that improve health and save lives. See how .
Small Business Portfolio Overview Active Small Business Awards Research Evaluation and Commercialization Hubs (REACH) Search Technologies from Academic Centers and Hubs Our team can help you maximize the benefits from NIH programs and resources which help you bring your innovations to life. We value biomedical innovation and strive to empower scientists and entrepreneurs to bring their discoveries to patients.
HHS Small Business Program Managers Non-dilutive funding for early-stage research and development. [ Parent Announcements ] [ Specific Opportunities ] More information on HHS SBIR contracts is available on the NIH SBIR contracts webpage . NIH has committed $20 million to support academic product development and innovation.
Learn more about the five new Research Evaluation and Commercialization Hubs (REACH) in the funding opportunity announcement (RFA-OD-23-005) Standard Application Due Dates are September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays are moved to the next business day. Some SBIR/STTR grant solicitations are focused on specific research areas.
Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program. National Institutes of Health Product Development Support Looking for the NIH SBIR & STTR site? The new seed.
nih. gov has everything you’re looking for about the NIH small business research and development programs (SBIR & STTR) . In addition, you can learn about other types of product development and commercialization support for NIH award recipients .
Questions? Check out About the NIH SEED Office or email us at [email protected] .
According to the current listing, eligibility includes: U.S. small business concerns (SBCs) that are organized for profit with a U.S. place of business, have ≤ 500 employees including affiliates, and are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof. Confirm the full requirements in the official notice before applying.
The current listing shows up to approximately $323,090 (Phase I); Up to $2,153,927 (Phase II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (Omnibus) is funded by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
Small Business Innovation Research Grant Parent SBIR [R43/R44] Clinical Trial Optional is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program provides non-dilutive funding for early-stage research and development (R&D) in biomedical technology with strong commercialization potential. It supports investigator-initiated ideas through parent grant announcements.
Small Business Technology Transfer Grant Parent STTR [R41/R42] Clinical Trial Optional is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). Similar to SBIR, the STTR program focuses on funding research and development. The core difference is the requirement for a formal collaboration between the small business and an eligible non-profit research institution.
NIH Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA). This program supports small businesses conducting research and development (R&D) to develop commercial products that enhance health and well-being. It is a major source of early-stage funding for U.S. technology development and commercialization in biomedical and behavioral research, including medical devices, health IT, and digital health. Phase I focuses on establishing technical merit and feasibility. The program is offered by NIH, CDC, and FDA.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Extramural Loan Repayment Program pays up to $50,000 a year against educational debt at roughly a 50% success rate — better odds than almost any NIH research grant. For FY2027 the six extramural subcategories collapse into three: L30, L40, and L70. Applicants who would have used L32, L50, or L60 must now pick a new lane. Here is the crosswalk, the 20% debt-to-salary rule, and why the consolidation changes how you frame the research.
Read articleNOT-OD-26-098 bars K award funds from supporting clinical trials, feasibility studies, and ancillary studies for due dates on or after October 12, 2027, and retires the Independent Clinical Trial Required K NOFOs. NIH has no replacement mechanism yet — only an RFI closing September 30, 2026. Here is what the policy actually says, who it hits, and how to sequence around it.
Read article